RxDoctor Payments Data

Anne Marceau, APRN

Nurse Practitioner · Salt Lake City, UTNPI 1265482012

Payments from drug & device makers

$2,610in general payments, 2019–2025

Across 75 payments — averaging $34.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Beigene USA, Inc.$791
  • Astellas Pharma US Inc$254
  • Pfizer$221
  • Seagen Inc.$194
  • AstraZeneca$185
  • Johnson & Johnson$155
  • plus $810 from 16 others

What the payments were for

  • Consulting fees$65025%
  • Food & beverage$1,41854%
  • Education$54221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,610 in reported general payments places this provider in the 85th percentile of 979 nurse practitioner providers in Utah.

See all nurse practitioner providers in Utah

Medicare billing

Part B allowed, 2024
$344,412
Medicare patients
59
Services billed
16,556

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban15$14,351
Imatinib Mesylate17$1,531
Hydroxyurea55$1,466
Tamoxifen Citrate20$511
Ibuprofen13$329
Prednisone41$265
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen11$189
Oxycodone Hcl14$186
Ondansetron Hcl21$171
Prochlorperazine Maleate12$168
Acyclovir17$164
Temazepam13$161
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim27$150
Bicalutamide12$147
Levothyroxine Sodium16$91

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$155$14,35115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 979 nurse practitioner providers in Utah.

Other nurse practitioner in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →